業績

令和4年度フラテ研究奨励賞 久田 諒先生

  • 2023
  • 膠原病グループ
  • 受賞

Masato Tarumi, Nobuya Abe, Tatsuya Atsumi.

Progressive cognitive dysfunction with subdural polycystic hygroma and systemic inflammation under immunosuppressive therapy.

Int J Rheum Dis 2023, in press.

IF: 2.558

  • 2023
  • 膠原病グループ
  • 欧文論文/症例報告

Nakamura J, Tsujino I, Shima H, Nakaya T, Sugimoto A, Sato T, Watanabe T, Ohira H, Suzuki M, Tsuneta S, Hisada R, Kato M, Konno S.

Clinical and hemodynamic response to imatinib in pulmonary veno-occlusive disease/pulmonary capillary hemangiomatosis: a pilot study of five cases.

American Journal of Cardiovascular Drugs. in press.

IF= 3.290

  • 2023
  • 膠原病グループ
  • 欧文論文/原著

Aso K, Kono M, Kanda M, Kudo Y, Sakiyama K, Hisada R, Karino K, Ueda Y, Nakazawa D, Fujieda Y, Kato M, Amengual O and Atsumi T.

Itaconate ameliorates autoimmunity by modulating T cell imbalance via metabolic and epigenetic reprogramming.

Nature Commun. in press.

  • 2023
  • 膠原病グループ
  • 欧文論文/原著

Nomoto H.

Fixed-ratio combinations of basal insulin and glucagon-like peptide-1 receptor agonists as a promising strategy for treating diabetes World J Diabetes

IF:4.560

  • 2023
  • 糖尿病・内分泌グループ
  • 欧文論文/総説

令和4年度 北海道大学大学院医学研究院 優秀論文賞 阿部 靖矢先生

  • 2023
  • 膠原病グループ
  • 受賞

令和4年度 北海道大学大学院医学研究院 優秀論文賞 狩野 皓平先生

  • 2023
  • 膠原病グループ
  • 受賞

Takako Araki, Hiraku Kameda, Masaaki Yamamoto, Toru Tateno, Yasumasa Iwasaki, Run Yu, Constance Chik, Hiba Hashmi, Angela Radulescu, Lynn A Burmeister, Hidenori Fukuoka The impact of multi-cultural interfacility video case conference A novel education model after the COVID pandemic Journal of the Endocrine Society, in press.

IF:なし

  • 2023
  • 糖尿病・内分泌グループ
  • 欧文論文/原著

Takahashi Y, Nomoto H*, Yokoyama H, Takano Y, Nagai S, Tsuzuki A, Cho KY, Miya A, Kameda H, Takeuchi J, Taneda S, Kurihara Y, Atsumi T, Nakamura A, Miyoshi H*.

Improvement of glycemic control and treatment satisfaction by switching from liraglutide or dulaglutide to subcutaneous semaglutide in patients with type 2 diabetes: A multicenter, prospective, randomized, open-label, parallel-group comparison study (SWITCH-SEMA 1

study)

Diabetes Obes Metab, in press

IF = 6.408

  • 2023
  • 糖尿病・内分泌グループ
  • 欧文論文/原著

Miyoshi H, Matsuhisa M, Yabe D, Takahashi Y, Morimoto Y, Terauchi Y.

Use of iGlarLixi for the management of type 2 diabetes in Japanese clinical practice: prior treatment subgroup analysis of the SPARTA Japan study.

Diabetes Ther. 2023 in press

IF = 3.605

  • 2023
  • 糖尿病・内分泌グループ
  • 欧文論文/原著